Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00189605
Other study ID # S-704LB
Secondary ID
Status Completed
Phase Phase 4
First received September 13, 2005
Last updated August 25, 2015
Start date September 2004
Est. completion date April 2009

Study information

Verified date August 2015
Source ArthroCare Corporation
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The goal of this post-marketing surveillance study is to compare two procedures which are used to treat patients who require a disc decompression procedure. These procedures are: 1) plasma disc decompression procedure using Coblation technology and 2) fluoroscopy guided transforaminal epidural steroid injection (TFESI). The study will evaluate treatment efficacy and rate of improvement in symptoms through the first six months following the procedure.

The principal objectives of this study are to determine whether subjects receiving the plasma disc decompression procedure demonstrate:

1. Improved clinical outcomes over subjects receiving TFESI

2. More rapid reversal of symptoms than subjects receiving TFESI


Description:

Chronic leg and back pain are two of the most common ailments in our society, and are associated with serious financial and social consequences. One surgical treatment modality is plasma disc decompression, based on the principle that inducing a small reduction of volume in the closed hydraulic space of an intact (contained herniated) disc can relieve pressure, and thereby reduce or eliminate pain. Another widely accepted treatment is transforaminal epidural steroid injection (TFESI), which delivers a high concentration of corticosteroid to the targeted disc nerve interface, and is thought to decrease pain by reducing inflammation.

This study proposes to compare the efficacy of the plasma disc decompression procedure to the standard TFESI series in patients who have failed to improve after an initial TFESI injection. The goal is to better understand the differences between these two treatment modalities and to monitor the rates of symptom improvement through the first six months between patients receiving a series of at least two selective nerve root injections and those undergoing the one-time plasma disc decompression procedure after failing one fluoroscopy guided TFESI. Patients will continue to be monitored over the 2-year post-procedure period to assess stability of treatment effect.


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date April 2009
Est. primary completion date December 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Patient has one symptomatic contained, focal herniated lumbar disc.

2. Patient's age should be at least 18 years old and no more than 75 years old.

3. Selective nerve root injection or epidural steroid injection for symptomatic herniated disc, received between 3 weeks and six months ago.

4. A VAS score for radicular pain of 50 or greater on a scale of 0 to 100.

5. Radicular pain concordant with image findings (MRI or CT).

6. Disc height greater than 50%.

7. Patient signs informed consent.

Exclusion Criteria:

1. Patient is pregnant, or pregnancy is suspected or planned within the study timeframe.

2. Patient is receiving Worker's compensation or is in litigation related to back/leg pain.

3. Patient has a cardiac pacemaker, automatic defibrillator, or any peripheral stimulator leads in the lumbar area.

4. Allergy to contrast media or drugs to be used in the intended procedure.

5. Medical co-morbidities that preclude surgical intervention.

6. Patient is receiving anti-psychotic therapy.

7. Patient is a prisoner.

8. Patient is incapable of understanding or responding to the study questionnaires.

9. History of previous spinal surgery at, or directly adjacent to, the level to be treated.

10. Patient is morbidly obese (BMI = 40).

11. Patient is simultaneously participating in another device or drug study related to limb/axial pain.

12. Patient has a spinal fracture, tumor or infection.

13. Radicular pain originating from more than one disc level.

14. Axial (back) pain greater than radicular (leg) pain.

15. Clinical evidence of cauda equina syndrome.

16. Progressive neurologic deficit.

17. Radiological evidence of spondylolisthesis at the level to be treated.

18. Radiological evidence of moderate/severe stenosis at the level to be treated.

19. Evidence of extruded or sequestered disc herniation on magnetic resonance imaging.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Perc-DLR/Perc-DLG
Device technique will be used per IFU
Drug:
Fluoroscopy guided transforaminal epidural steroid injection (TFESI)
Injection of steroid solution into the lumbar level

Locations

Country Name City State
United States The University of Michigan, The Spine Program Ann Arbor Michigan
United States Beth Israel Deaconess Medical Center, Arnold Pain Management Center, Boston Massachusetts
United States University of Vermont College of Medicine, Center for Pain Mgmt Burlington Vermont
United States OrthoCarolina Charlotte North Carolina
United States Medical Advanced Pain Specialists (MAPS) Edina Minnesota
United States Innovative Spine Care Little Rock Arkansas
United States TRIA Orthropaedic Center Minneapolis Minnesota
United States SpectrumCare Rehabilitation Medical Center Inc. Napa California
United States University of Pittsburgh Medical Center (UPMC) Presbyterian Pittsburgh Pennsylvania
United States Western Pennsylvania Hospital Pittsburgh Pennsylvania
United States Consultants in Pain Research San Antonio Texas
United States The Orthopedic Clinic Association Scottsdale Arizona
United States North Valley Rehabilitation Hospital Thornton Colorado

Sponsors (1)

Lead Sponsor Collaborator
ArthroCare Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain status change assessed using a visual analogue scale (VAS) for radicular pain intensity. 6 weeks, 3 mos., 6 mos., 1 year, 2 years No
Secondary Functional status change evaluated using the Oswestry Disability Questionnaire. 6 weeks, 3 mos., 6 mos., 1 year, 2 years No
Secondary General health status change determined using the SF-36. 6 weeks, 3 mos., 6 mos., 1 year, 2 years No
Secondary Employment status change examined using a questionnaire developed by the American Academy of Orthopaedic Surgeons (AAOS) and the North American Spine Society (NASS). 6 weeks, 3 mos., 6 mos., 1 year, 2 years No
Secondary Subject global satisfaction post-procedure assessed using a global satisfaction statement. 6 weeks, 3 mos., 6 mos., 1 year, 2 years No
Secondary Change in frequency and type of pain medication use. 6 weeks, 3 mos., 6 mos., 1 year, 2 years No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05487690 - Application of 3D Printing Guide Plate in Spinal Minimally Invasive and Interventional Surgeries N/A
Not yet recruiting NCT05632835 - Application of 3D Printing Guide Plate in Endoscopic Spinal Surgery N/A
Completed NCT01205464 - Effects of Doxycycline on Persistent Symptoms Post-neuroborreliosis N/A
Not yet recruiting NCT05610553 - Application of 3D Printing Guide Plate in Percutaneous Disc Decompression N/A
Active, not recruiting NCT00880828 - Comparing Two Different Cervical Collars for the Treatment in Patient With Cervical Radiculopathy and Radicular Pain N/A
Recruiting NCT00516009 - Efficacy of Intravenous Dexamethasone for Acute Disc Herniation-Induced Sciatica N/A
Recruiting NCT05747807 - Percutaneous Intradiscal Radiofrequency as A Treatment for Radicular Pain From Lumbar Disc Herniation N/A